These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25004651)

  • 1. PET scanning: worth the cost in cancer? Not only worth the cost, but sometimes a cost-cutter!
    Rohren EM
    Oncology (Williston Park); 2014 May; 28(5):390, 392. PubMed ID: 25004651
    [No Abstract]   [Full Text] [Related]  

  • 2. How can we tell if PET imaging for cancer is cost effective?
    Mac Manus MP; Hicks RJ
    Lancet Oncol; 2010 Aug; 11(8):711-2. PubMed ID: 20688268
    [No Abstract]   [Full Text] [Related]  

  • 3. PET scanning: worth the cost in cancer? Not for all cancers--it's not reliable enough yet.
    Krishnamoorthy SK; Saif MW
    Oncology (Williston Park); 2014 May; 28(5):391-2. PubMed ID: 25004652
    [No Abstract]   [Full Text] [Related]  

  • 4. CMS and PET for solid tumors.
    Cannon H
    J Nucl Med; 2008 Dec; 49(12):23N. PubMed ID: 19038994
    [No Abstract]   [Full Text] [Related]  

  • 5. Positron-emission tomography and assessment of cancer therapy.
    Juweid ME; Cheson BD
    N Engl J Med; 2006 Feb; 354(5):496-507. PubMed ID: 16452561
    [No Abstract]   [Full Text] [Related]  

  • 6. PET imaging for Alzheimer disease: are its benefits worth the cost?
    Mitka M
    JAMA; 2013 Mar; 309(11):1099-100. PubMed ID: 23512036
    [No Abstract]   [Full Text] [Related]  

  • 7. [Methods for evaluating the economic efficiency of the project of PET-center's creation in conditions of a specialized medical institution].
    Karitsky AP
    Vopr Onkol; 2016; 62(1):7-13. PubMed ID: 30444326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [IV. Hungarian PET/CT Multidisciplinary Consensus Conference -- position statement].
    Katalin B; István S; Miklós K;
    Magy Onkol; 2011 Jun; 55(2):117-27. PubMed ID: 21780330
    [No Abstract]   [Full Text] [Related]  

  • 9. PET coverage extended. Medicare won't stop covering post-treatment scans.
    Zigmond J
    Mod Healthc; 2013 Jun; 43(24):24. PubMed ID: 23875236
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost effectiveness of positron emission tomography in Canada.
    Sloka JS; Hollett PD
    Med Sci Monit; 2005 Oct; 11(10):PH1-6. PubMed ID: 16192911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
    Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
    J Nucl Med Technol; 2010 Mar; 38(1):6-17. PubMed ID: 20197541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
    Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
    J Nucl Med; 2010 Mar; 51(3):401-12. PubMed ID: 20150250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/CT is a cost-effective tool against cancer: synergy supersedes singularity.
    Fischer BM; Siegel BA; Weber WA; von Bremen K; Beyer T; Kalemis A
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1749-52. PubMed ID: 27178271
    [No Abstract]   [Full Text] [Related]  

  • 14. Contribution of imaging to cancer care costs.
    Yang Y; Czernin J
    J Nucl Med; 2011 Dec; 52 Suppl 2():86S-92S. PubMed ID: 22144560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis.
    Mansueto M; Grimaldi A; Mangili G; Picchio M; Giovacchini G; Viganò R; Messa C; Fazio F
    Eur J Cancer Care (Engl); 2009 Nov; 18(6):612-9. PubMed ID: 19549284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ["Check-up" offer to managers: is screening for early recognition of disease being discredited?].
    Riemann JF
    Dtsch Med Wochenschr; 2010 Apr; 135(16):812. PubMed ID: 20391313
    [No Abstract]   [Full Text] [Related]  

  • 17. The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma.
    Yen RF; Yen MF; Hong RL; Tzen KY; Chien CR; Chen TH
    Acad Radiol; 2009 Jan; 16(1):54-60. PubMed ID: 19064212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare demonstration projects acknowledge evidence-based medicine in cancer care.
    Twombly R
    J Natl Cancer Inst; 2005 Jan; 97(1):6-7. PubMed ID: 15632369
    [No Abstract]   [Full Text] [Related]  

  • 19. The National Oncologic PET Registry: lessons learned for coverage with evidence development.
    Tunis S; Whicher D
    J Am Coll Radiol; 2009 May; 6(5):360-5. PubMed ID: 19394577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evidence-based use of the PET in cancer diagnosis?].
    Nygren P
    Lakartidningen; 2000 May; 97(22):2776, 2779. PubMed ID: 10900901
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.